Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 2021: Evaluating the Benefit of Concomitant TV Repair During Mitral Valve Surgery
Author(s): James Gammie Added: 2 years ago
In this short interview, Dr James Gammie (University of Maryland Medical Center, MD, US) discusses the findings from surgical trial assessing the benefit of concomitant tricuspid repair during mitral valve surgery. The trial, presented at AHA 2021, demonstrated that at 2 years, TA had no impact on MACCE, survival, or QOL. Discussion Points 1. Reasoning for this Study 2. Study Design and… View more

Vascular Disease and Surgery

Intervention
Contemporary Management of Secondary Mitral Regurgitation
Author(s): Kashish Goel , Colin M Barker , JoAnn Lindenfeld Added: 3 years ago
Heart failure (HF) is a growing epidemic, with an estimated 6.2 million adults (≥20 years) affected between 2013 and 2016 in the US.1 The prevalence is increasing and is expected to reach 8 million by 2030.1 Mitral regurgitation (MR) is common in HF patients, especially in those with ischaemia, left ventricular (LV) dysfunction or dilated cardiomyopathy. MR in the absence of structural… View more

Vascular Disease and Surgery

Heart Failure
ESC 23: The SurHyb Trial
Author(s): Alan Bulava Added: 7 months ago
ESC 2023 — Dr Alan Bulava (Ceske Budejovice Hospital and University of South Bohemia, CZ) joins us in this succinct interview to discuss the findings from the SurHyb trial. The SurHyb study was a prospective, open-label-multicentre randomized trial. The study aimed to evaluate CryoMaze surgery alone, as compared to CryoMaze followed by radiofrequency catheter ablation 3-months post-surgery. … View more

Electrophysiology & Arrhythmia
TCT 23: Late-Breaking Clinical Trials Revealed
Added: 6 months ago Source:  Radcliffe Cardiology
Find out what's hot at TCT in this preview from Prof Nicolas Van Mieghem and Dr Joost Daemen The Cardiovascular Research Foundation (CRF) has unveiled the late-breaking clinical trials scheduled for presentation at the 2023 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting taking place from October 23 to 26 in San Francisco. TCT is renowned for showcasing groundbreaking research in… View more
Author(s): Michael Hoebartner , Philipp Kiefer , Michael Andrew Borger , et al Added: 3 years ago
Mitral valve regurgitation (MR) is frequently induced by degenerative mitral valve (MV) disease and leads to leaflet prolapse. Therefore, valve repair is a well-proven surgical technique with excellent long-term outcomes.1–5 The risk of declining left ventricle (LV) function or LV enlargement and the development of atrial fibrillation or severe pulmonary hypertension due to chronic volume… View more

Intervention

Vascular Disease and Surgery
Author(s): David Messika-Zeitoun , Jean-Michel Serfaty , Dominique Himbert , et al Added: 3 years ago
Functional mitral regurgitation is a regurgitation that occurs despite a structurally normal mitral valve as a consequence of left ventricular dysfunction. It is a common feature of both dilated and ischaemic cardiomyopathy, and the presence and degree of severity of mitral regurgitation is associated with an increased risk of death and congestive heart failure.1–3 Mechanisms leading to… View more

Imaging & Diagnostics
AHA 2021: Late-breaking Science Video Collection
Author(s): Anushka Patel , Stephen Nicholls , Jeffrey Weitz , et al Added: 2 years ago
Our regular review seriesView from the Thoraxcenterhosted by Prof Nicolas Van MieghemandDr Joost Daemen provide aconcise and insightful preview of the late-breaking science presented at AHA Scientific Sessions 2021. For a deep-dive, watch Dr Harriette Van Spall's Late-breaking Discussion series on highly expected trials with principal investigators. Short, accessibleExpert Interviewswill be… View more

Vascular Disease and Surgery

Standards & Guidelines
Author(s): Michele De Bonis , Ottavio Alfieri Added: 3 years ago
Degenerative mitral regurgitation (MR) represents a rather common pathology, affecting 1–2% of the general population. In patients requiring surgery for this disease, mitral valve repair is the standard of care. Whenever feasible it is preferable to prosthetic replacement, as it provides better preservation of left ventricular (LV) function, higher survival, lower rates of thromboembolism and… View more

Vascular Disease and Surgery

Intervention
APSC Consensus Recommendations for MitraClip in MR
Author(s): Khung Keong Yeo , Jack Wei Chieh Tan , David WM Muller , et al Added: 2 years ago

Intervention
TCT 23: 5 Trials That Changed My Practice
Author(s): Mirvat Alasnag Added: 5 months ago
TCT 23 - We are joined by Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, SA) for an insightful summary of the late-breaking trials that are expected to have an impact on interventional science and clinical practice. Trials covered in detail include: Agent IDE ALIGN-AR PARTNER 3 EVOLUT Low-Risk TRISCEND Recorded remotely from Jeddah, 2023. Editor: Jordan Rance Video Specialist:… View more

Intervention